Skip to main content

Advertisement

SpringerLink
Log in

Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT)

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Objectives

This study aims to evaluate the quality of care (QOC) and use of validated risk algorithms provided in a specialized osteoporosis clinic to men with prostate cancer on androgen deprivation therapy (ADT) who are at risk of bone loss and fragility fractures.

Patients and methods

Charts for 100 consecutive men (mean age 73.0 years) on ADT referred to a tertiary osteoporosis clinic in Toronto, Canada between 2010 and 2014 were reviewed. The following QOC issues were examined: (a) bone health services provided, i.e., screening, preventing, and treating osteoporosis; and (b) use of national guidelines and fracture risk assessment tools for targeting appropriate therapy.

Results

The median (IQR) duration of ADT was 21.4 (26.9) months at the baseline visit. Nineteen patients had their first bone mineral density test before starting ADT and 34 during the first year of use. At initial consultation, 83 and 30 patients were taking inadequate amounts of calcium and vitamin D, respectively. A validated fracture risk assessment tool was used in all patients; 42 had a moderate 10-year fracture risk and 12 were high risk. Sixteen (72.7 %) of sedentary patients were advised to increase physical activity. Sixty-four (77.1 %) and 28 (93.3 %) of patients not taking appropriate amounts of calcium and vitamin D, respectively, were recommended to adjust their intake to guideline levels. All patients at high fracture risk were recommended a bisphosphonate.

Conclusions

The majority of referred patients had moderate to high fracture risk. The osteoporosis clinic recommended guideline-based bone health care for the vast majority of men on ADT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2015) Canadian Cancer Statistics 2015. Canadian Cancer Society, Toronto

    Google Scholar 

  2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29

    Article  PubMed  Google Scholar 

  3. Ganz PA (2009) Survivorship: adult cancer survivors. Prim Care 36:721–741

    Article  PubMed  Google Scholar 

  4. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772–2780

    Article  PubMed  Google Scholar 

  5. Loblaw DA, Virgo KS, Nam R, et al. (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596–1605

    Article  CAS  PubMed  Google Scholar 

  6. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60:7–11 discussion 11–12

    Article  CAS  PubMed  Google Scholar 

  7. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615–1624

    Article  CAS  PubMed  Google Scholar 

  8. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244

    Article  CAS  PubMed  Google Scholar 

  9. Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201–215

    Article  PubMed  Google Scholar 

  10. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM (2008) Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 26:4426–4434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800–805

    Article  CAS  PubMed  Google Scholar 

  12. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504

    Article  PubMed  Google Scholar 

  13. Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621–629

    Article  PubMed  Google Scholar 

  14. Panju AH, Breunis H, Cheung AM, et al. (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 103:753–757

    Article  CAS  PubMed  Google Scholar 

  15. Alibhai SM, Mohamedali HZ, Gulamhusein H, et al. (2013) Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int

  16. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822

    Article  CAS  PubMed  Google Scholar 

  17. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164

    Article  CAS  PubMed  Google Scholar 

  18. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184:918–924

    Article  PubMed  Google Scholar 

  19. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27:3452–3458

    Article  PubMed  Google Scholar 

  20. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007

    Article  PubMed  Google Scholar 

  21. Papaioannou A, Morin S, Cheung AM, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873

    Article  PubMed  PubMed Central  Google Scholar 

  22. Duncan GG, Corbett T, Lukka H, Warde P, Pickles T (2006) GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13:2962–2966

    PubMed  Google Scholar 

  23. Carroll PR, Parsons JK, Andriole G, et al. (2014) Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 12:1211–1219 quiz 1219

    CAS  Google Scholar 

  24. Gralow JR, Biermann JS, Farooki A, et al. (2009) NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Cancer Netw 7(Suppl 3):S1–32 quiz S33-35

    Google Scholar 

  25. Datta M, Schwartz GG (2012) Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 17:1171–1179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307:255–256

    Article  CAS  PubMed  Google Scholar 

  27. Alibhai SM, Rahman S, Warde PR, Jewett MA, Jaffer T, Cheung AM (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists. Urology 68:126–131

    Article  PubMed  Google Scholar 

  28. Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T, Adachi JD, Papaioannou A (2012) The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. J Oncol 2012:958596

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tanvetyanon T (2005) Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103:237–241

    Article  PubMed  Google Scholar 

  30. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME (2006) Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 40:2107–2114

    Article  PubMed  Google Scholar 

  31. Gulamhusein H, Yun L, Cheung AM, Sutradhar R, Paszat L, Warde P, Alibhai SM (2014) Bisphosphonate prescriptions in men with androgen deprivation therapy use. JAMA 312:2285–2286

    Article  PubMed  Google Scholar 

  32. Soeyonggo T, Warde P, Fleshner N, Timilshina N, Alibhai SM (2012) Information needs of men on androgen deprivation therapy. BJU Int 109:1503–1509

    Article  PubMed  Google Scholar 

  33. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  34. Hung A, Hamidi M, Riazantseva E, Thompson L, Tile L, Tomlinson G, Stewart B, Cheung AM (2011) Validation of a calcium assessment tool in postmenopausal Canadian women. Maturitas 69:168–172

    Article  CAS  PubMed  Google Scholar 

  35. World Health Organization (1994) Assessment of fracture risk and application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva, Switzerland

  36. Dhanapal V, Reeves DJ (2012) Bone health management in prostate cancer patients receiving androgen deprivation therapy. J Oncol Pharm Pract 18:84–90

    Article  PubMed  Google Scholar 

  37. Nadler M, Alibhai SMH, Catton P, Catton C, To MJ, Jones J (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in men on androgen deprivation therapy for prostate cancer. BJU Int 111:1301–1309

    Article  CAS  PubMed  Google Scholar 

  38. Theodorou M, Stafylas P, Kourlaba G, Kaitelidou D, Maniadakis N, Papademetriou V (2012) Physicians’ perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. Int J Hypertens 2012:503821

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ahmad N, Hassan Y, Tangiisuran B, Meng OL, Abd Aziz N, Ahmad FU, Atif M (2013) Guidelines adherence and hypertension control at a tertiary hospital in Malaysia. J Eval Clin Pract 19:798–804

    PubMed  Google Scholar 

  40. Schou M, Gislason G, Videbaek L, Kober L, Tuxen C, Torp-Pedersen C, Hildebrandt PR, Gustafsson F, NorthStar I (2014) Effect of extended follow-up in a specialized heart failure clinic on adherence to guideline recommended therapy: NorthStar Adherence Study. Eur J Heart Fail 16:1249–1255

    Article  CAS  PubMed  Google Scholar 

  41. Luttik ML, Jaarsma T, van Geel PP, et al. (2014) Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 16:1241–1248

    Article  PubMed  Google Scholar 

  42. Hall LN, Shrader SP, Ragucci KR (2009) Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic. Ann Pharmacother 43:1781–1786

    Article  PubMed  Google Scholar 

  43. Alberta Health Services (2007) Prostate cancer. Clinical practice guideline GU-004. Edmonton, AB

  44. BC Cancer Agency (BCCA) (2008) Guidelines for the prevention of osteoporosis for men with prostate cancer on hormone therapy. BCCA, Vancouver, BC

    Google Scholar 

  45. Barton MK (2013) Low rate of bone density testing in men receiving androgen deprivation therapy. CA Cancer J Clin 63:85–86

    Article  PubMed  Google Scholar 

  46. Blonk MC, Erdtsieck RJ, Wernekinck MG, Schoon EJ (2007) The fracture and osteoporosis clinic: 1-year results and 3-month compliance. Bone 40:1643–1649

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University Health Network, Toronto, ON, Canada

    Rehab Chahin, Husayn Gulamhusein, Henriette Breunis & Shabbir M.H. Alibhai

  2. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Shabbir M.H. Alibhai

  3. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Shabbir M.H. Alibhai

  4. Toronto General Hospital, 200 Elizabeth St, Room EN14-214, Toronto, ON, M5G 2C4, Canada

    Shabbir M.H. Alibhai

Authors
  1. Rehab Chahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Husayn Gulamhusein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henriette Breunis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shabbir M.H. Alibhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shabbir M.H. Alibhai.

Ethics declarations

Conflict of interest

This review study did not receive funding. None of the authors have any financial conflicts of interest to disclose relating to this study. Dr. Alibhai has full control of all primary data and agrees to allow the journal to review the data if requested.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chahin, R., Gulamhusein, H., Breunis, H. et al. Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT). Support Care Cancer 24, 4713–4720 (2016). https://doi.org/10.1007/s00520-016-3320-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-016-3320-1

Keywords

Search

Navigation